Committee Questions for Topic 1:

1) For the influenza A (H1N1) component of the 2020-2021 influenza virus vaccines in the U.S., does the committee recommend:
   - An A/Guangdong-Maonan/SWL1536/2019 (H1N1)pdm09-like virus for egg-based vaccines
   - An A/Hawaii/70/2019 (H1N1)pdm09-like virus for cell- or recombinant-based Vaccines

2) For the influenza A (H3N2) component of the 2020-2021 influenza virus vaccine in the U.S., does the committee recommend:
   - An A/Hong Kong/2671/2019 (H3N2)-like virus for egg-based vaccines
   - An A/Hong Kong/45/2019 (H3N2)-like virus for cell- or recombinant-based vaccines

3) For the influenza B component of the 2020-2021 trivalent influenza virus vaccine in the U.S., does the committee recommend inclusion of a B/Washington/02/2019-like virus (B/Victoria lineage)

4) For quadrivalent 2020-2021 influenza vaccines in the U.S., does the committee recommend inclusion of a B/Phuket/3073/2013-like virus (B/Yamagata lineage) as the 2nd influenza B strain in the vaccine